(0.20%) 5 142.00 points
(0.21%) 38 520 points
(0.26%) 17 892 points
(-0.92%) $83.08
(1.61%) $1.954
(-0.14%) $2 344.00
(-0.13%) $27.50
(0.34%) $925.20
(-0.20%) $0.933
(-0.18%) $11.00
(-0.28%) $0.798
(1.14%) $92.92
Live Chart Being Loaded With Signals
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...
Stats | |
---|---|
本日の出来高 | 451 947 |
平均出来高 | 326 336 |
時価総額 | 17.12B |
EPS | $0 ( 2024-04-25 ) |
Last Dividend | $0.220 ( 2021-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 477.50 |
ATR14 | $0.0110 (0.12%) |
ボリューム 相関
Astellas Pharma Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Astellas Pharma Inc. 相関 - 通貨/商品
Astellas Pharma Inc. 財務諸表
Annual | 2024 |
収益: | $1 603.67B |
総利益: | $1 212.37B (75.60 %) |
EPS: | $9.50 |
FY | 2024 |
収益: | $1 603.67B |
総利益: | $1 212.37B (75.60 %) |
EPS: | $9.50 |
FY | 2023 |
収益: | $1 518.62B |
総利益: | $1 191.83B (78.48 %) |
EPS: | $54.24 |
FY | 2022 |
収益: | $1 296.16B |
総利益: | $1 014.87B (78.30 %) |
EPS: | $67.08 |
Financial Reports:
No articles found.
Astellas Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.192 | 2021-03-29 |
Last Dividend | $0.220 | 2021-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.412 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.22 | -- |
Div. Sustainability Score | 8.96 | |
Div.Growth Potential Score | 5.70 | |
Div. Directional Score | 7.33 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MUEL | Ex Dividend Junior | 2023-08-28 | Sporadic | 0 | 0.00% | |
CNTHP | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
SWRAY | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
HNFSA | Ex Dividend Junior | 2023-08-09 | Quarterly | 0 | 0.00% | |
ATDRY | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
OSCUF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
DQJCF | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
TSGTY | Ex Dividend Knight | 2023-06-23 | Annually | 0 | 0.00% | |
JDVB | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
BMBN | Ex Dividend Knight | 2023-06-30 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00805 | 1.500 | 9.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00362 | 1.200 | 9.88 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00817 | 1.500 | -1.020 | -1.530 | [0.1 - 1] |
payoutRatioTTM | 9.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.929 | 0.800 | -0.354 | -0.283 | [1 - 3] |
quickRatioTTM | 0.687 | 0.800 | -0.663 | -0.530 | [0.8 - 2.5] |
cashRatioTTM | 0.261 | 1.500 | 9.66 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.258 | -1.500 | 5.70 | -8.56 | [0 - 0.6] |
interestCoverageTTM | 14.83 | 1.000 | 5.62 | 5.62 | [3 - 30] |
operatingCashFlowPerShareTTM | 101.11 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 55.11 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.576 | -1.500 | 7.69 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.756 | 1.000 | 0.733 | 0.733 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.111 | 1.000 | 9.78 | 9.78 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0162 | -0.0162 | [0.2 - 2] |
assetTurnoverTTM | 0.449 | 0.800 | -0.338 | -0.271 | [0.5 - 2] |
Total Score | 8.96 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 209.44 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00817 | 2.50 | -0.656 | -1.530 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 55.11 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0243 | 1.500 | 9.39 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 101.11 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 9.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.401 | 1.500 | -0.661 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.113 | 1.000 | 9.67 | 0 | [0.1 - 0.5] |
Total Score | 5.70 |
Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。